A patent for a combination brimonidine/ timolol eye-drop product used for treating glaucoma was invalid as obvious. It was common at the time of invention to provide brimonidine and timolol to a patient in serial fashion. Prior art taught that patient compliance could be increased by combining drugs in a fixed-combination formulation. There was no indication that the prior art as a whole taught away from the invention.
展开▼
